The bacterial virulence factor NleA's involvement in intestinal tight junction disruption during enteropathogenic E. coli infection is independent of its putative PDZ binding domain

Gut Microbes

Volumn 1, Issue 2, 2010, Pages 114-118

  Thanabalasuriar, Ajitha ^a   Koutsouris, Athanasia ^b   Hecht, Gail ^b   Gruenheid, Samantha ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Bacterial pathogenesis; EPEC; Infection; Tight junction; Type III secretion

Indexed keywords

BACTERIAL PROTEIN; PDZ PROTEIN; PROTEIN NLEA; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CARBOXY TERMINAL SEQUENCE; ENTEROPATHOGENIC ESCHERICHIA COLI INFECTION; HUMAN; NONHUMAN; PDZ DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; TIGHT JUNCTION; TYPE III SECRETION SYSTEM;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 77954835412     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.4161/gmic.1.2.11685     Document Type: Article

References (25)

1. Chen DH, Frankel G. Enteropathogenic Escherichia coli: unravelling pathogenesis. FEMS Microbiol Rev 2005; 29:83-98.
2. Guttman JA, Finlay BB. Tight junctions as targets for infectious agents. Biochimica et Biophysica Acta 2009; 1788:832-41.
3. Gruenheid S, Finlay B. Microbial pathogenesis and cytoskeletal function. Nature 2003; 422:775-81.
4. Spitz J, Yuhan R, Koutsouris A, Blatt C, Alverdy J, Hecht G. Enteropathogenic Escherichia coli adherence to intestinal epithelial monolayers diminishes barrier function. Am J Physiol 1995; 268:374-9.
5. Canil C, Rosenshine I, Ruschkowski S, Donnenberg MS, Kaper JB, Finlay BB. Enteropathogenic Escherichia coli decreases the transepithelial electrical resistance of polarized epithelial monolayers. Infect Immun 1993; 61:2755-62.
6. Yuhan R, Koutsouris A, Savkovic SD, Hecht G. Enteropathogenic Escherichia coli-induced myosin light chain phosphorylation alters intestinal epithelial permeability. Gastroenterology 1997; 113:1873-82.
7. Simonovic I, Arpin M, Koutsouris A, Falk-Krzesinski HJ, Hecht G. Enteropathogenic Escherichia coli activates ezrin, which participates in disruption of tight junction barrier function. Infect Immun 2001; 69:5679-88.
8. Simonovic I, Rosenberg J, Koutsouris A, Hecht G. Enteropathogenic Escherichia coli dephosphorylates and dissociates occludin from intestinal epithelial tight junctions. Cell Microbiol 2000; 2:305-15.
9. Philpott DJ, McKay DM, Sherman PM, Perdue H. Infection of T84 cells with enteropathogenic Escherichia coli alters barrier and transport functions. Am J Physiol 1996; 270:634-45.
10. Muza-Moons MM, Koutsouris A, Hecht G. Disruption of cell polarity by enteropathogenic Escherichia coli enables basolateral membrane proteins to migrate apically and to potentiate physiological consequences. Infect Immun 2003; 71:7069-78.
11. Dean P, Kenny B. Intestinal barrier dysfunction by enteropathogenic Escherichia coli is mediated by two effector molecules and a bacterial surface protein. Mol Microbiol 2004; 54:665-75.
12. McNamara BP, Koutsouris A, O'Connell CB, Nougayrede JP, Donnenberg MS, Hecht G. Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier function. J Clin Invest 2001; 107:621-9.
13. Matsuzawa T, Kuwae A, Abe A. Enteropathogenic Escherichia coli type III effectors EspG and EspG2 alter epithelial paracellular permeability. Infect Immun 2005; 73:6283-9.
14. Tomson FL, Viswanathan VK, Kanack KJ, Kanteti RP, Straub KV, Menet M, et al. Enteropathogenic Escherichia coli EspG disrupts microtubules and in conjunction with Orf3 enhances perturbation of the tight junction barrier. Mol Microbiol 2005; 56:447-64.
15. Coombes BK, Wickham ME, Mascarenhas M, Gruenheid S, Finlay BB, Karmali MA. Molecular analysis as an aid to assess the public health risk of non-O157 Shiga toxinproducing Escherichia coli strains. Appl Environ Microbiol 2008; 74:2153-60.
16. Mundy R, Jenkins C, Yu J, Smith H, Frankel G. Distribution of espI among clinical enterohaemorrhagic and enteropathogenic Escherichia coli isolates. J Med Microbiol 2004; 53:1145-9.
17. Wickham ME, Brown NF, Boyle EC, Coombes BK, Finlay BB. Virulence is positively selected by transmission success between mammalian hosts. Curr Biol 2007; 17:783-8.
18. Gruenheid S, Sekirov I, Thomas NA, Deng W, O'Donnell P, Goode D, et al. Identification and characterization of NleA, a non-LEE-encoded type III translocated virulence factor of enterohaemorrhagic coli O157:H7. Mol Microbiol 2004; 51:1233-49.
19. Mundy R, Petrovska L, Smollett K, Simpson N, Wilson RK, Yu J, et al. Identification of a novel Citrobacter rodentium type III secreted protein, EspI and roles of this and other secreted proteins in infection. Infect Immun 2004; 72:2288-302.
20. Kim J, Thanabalasuriar A, Chaworth-Musters T, Fromme JC, Frey EA, Lario PI, et al. The bacterial virulence factor NleA inhibits cellular protein secretion by disrupting mammalian COPII function. Cell Host Microbe 2007; 2:160-71.
21. Lee MCS, Miller EA, Goldberg J, Orci L, Schekman R. Bi-directional protein transport between the ER and Golgi. Annu Rev Cell Dev Bio 2004; 20:87-123.
22. Thanabalasuriar A, Koutsouris A, Weflen A, Mimee M, Hecht G, Gruenheid S. The bacterial virulence factor NleA is required for the disruption of intestinal tight junctions by enteropathogenic Escherichia coli. Cell Microbiol 2009; 12:31-41.
23. Pawson T, Nash P. Assembly of cell regulatory systems through protein interaction domains. Science 2003; 300:445-52.
24. Lee SF, Kelly M, McAlister A, Luck SN, Garcia EL, Hall RA, et al. A C-terminal class I PDZ binding motif of EspI/NleA modulates the virulence of attaching and effacing Escherichia coli and Citrobacter rodentium. Cell Microbiol 2008; 10:499-513.
25. Tonikian R, Zhang Y, Sazinsky SL, Currell B, Yeh J-H, Reva B, et al. A specificity map for the PDZ domain family. Plos Biol 2008; 6:2043-59.